![]() |
市场调查报告书
商品编码
1607745
奈米医药的全球市场:模式·用途·适应症·分子类型·不同地区的预测 (~2032年)Global Nanomedicine Market Research Report: Information by Modality, by Application, and by Indication, by Molecule Type, and by Region Forecast till 2032 |
全球奈米药物市场规模将从2023年的2,529.7亿美元成长到2024年的2,737.9亿美元,预测期内复合年增长率为12.48%,到2032年将成长到8,198.4亿美元。这一规模美元。
全球各种疾病发生率的增加以及与奈米医学产品开发相关的各种协议推动了市场的发展。
按地区划分,由于癌症患者患病率上升以及强大的研发基础设施,北美市场在2023年占据最大的市场占有率,超过38.14%。 2020 年,美国报告了 1,603,844 例新癌症病例和 602,347 例癌症死亡病例。每10万人新增癌症病例403例,癌症死亡144例。
由于奈米技术的进步和改善医疗保健的潜力,欧洲市场正在快速成长。该市场致力于用于监测、治疗和诊断的奈米级材料和技术的开发和应用,并且该市场受到个人化治疗需求不断增长和慢性病患病率上升的推动。由于其高昂的研发成本和优良的医疗基础设施,欧洲处于奈米医学突破的最前线。重点领域包括标靶药物传输系统、更好的癌症治疗和奈米级成像工具。
亚太地区也在快速成长,反映出人们对尖端医疗技术的兴趣和投资不断增加。由于多种因素,包括医疗保健需求的增加、慢性病的流行以及奈米技术研究的重大进展,预计该市场将继续快速成长。
本报告提供全球奈米医药的市场调查,市场定义和概要,市场成长的各种影响因素分析,市场规模的转变·预测,各种区分·地区/各主要国家的明细,竞争环境,主要企业简介等资讯。
Global Nanomedicine Market Research Report: Information by Modality (Treatments and Diagnostics), by Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, and Implants), and by Indication (Oncological Diseases, Infectious Diseases, Cardiovascular Diseases, Orthopedic Diseases, Neurological Diseases, Urological Diseases, Ophthalmological Diseases, Immunological Diseases, and Others), by Molecule Type (Nanoparticles [Albumin Particles, Inorganic Nanoparticles, Lipid Nanoparticle, Liposomes, and Others], Nanoshells, Nanotubes, and Nanodevices), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032
In 2023, the nanomedicine market was estimated at USD 252.97 billion. The Nanomedicine Market is expected to expand from USD 273.79 billion in 2024 to USD 819.84 billion by 2032, with a compound yearly growth rate (CAGR) of 12.48% over the forecast period (2024-2032).
The global market is being driven by increasing occurrences of various ailments around the world, as well as agreements related to nanomedicine product development.
Market Segment insights
The Nanomedicine Market is divided into two segments: treatments and diagnostics.
The Nanomedicine Market is divided into five applications: drug delivery, diagnostic imaging, vaccinations, regenerative medicine, and implants.
The Nanomedicine Market has been classified by indication: oncological illnesses, infectious diseases, cardiovascular diseases, orthopedic disorders, neurological diseases, urological diseases, ophthalmological diseases, immunological diseases, and others.
The Nanomedicine Market is divided into four segments based on molecule type: nanoparticles, nanoshells, nanotubes, and nanodevices.
Regional insights
The market is segmented into four regions: North America, Europe, Asia-Pacific, and the rest of the world. North America held the biggest market share of more than 38.14% in 2023, owing to the rising prevalence of cancer cases and a strong research and development infrastructure. For example, in 2020, the United States reported 1,603,844 new cancer cases and 602,347 cancer deaths. There were 403 new cancer cases reported per 100,000 people, with 144 people dying from cancer.
The market for nanomedicine in Europe is rapidly developing as a result of advances in nanotechnology and its potential to improve healthcare. This market covers the development and application of nanoscale materials and technologies for monitoring, therapy, and diagnostics. The market is developing as a result of increased demand for tailored therapy and the rising prevalence of chronic diseases. Europe is at the forefront of nanomedicine breakthroughs, thanks to its high R&D spending and excellent healthcare infrastructure. Targeted drug delivery systems, better cancer therapies, and nanoscale imaging tools are key areas of focus.
The Asia-Pacific nanomedicine industry is rapidly developing, reflecting the region's increased interest and investment in cutting-edge healthcare technology. The market is predicted to grow fast due to several factors, including increased healthcare demand, rising chronic illness prevalence, and significant advances in nanotechnology research.
Sanofi (France), Johnson & Johnson Services, Inc. (US), Parvus Therapeutics Inc. (US), Nanobiotix (France), Ascendia Pharmaceuticals (US), Bristol-Myers Squibb Company (US), Jazz Pharmaceuticals (Ireland), Cytimmune Sciences, Inc. (US), Nanospectra Biosciences (US), and Pfizer, Inc. (US) are among the key companies in the nanomedicine market.